WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. EST on Tuesday, February 12, 2008 following the after-market release of its financial results for the fourth quarter and year ended December 31, 2007. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company’s product development programs and business activities.
